Company registration number 06983940 (England and Wales)
HEALTH2WORKS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
PAGES FOR FILING WITH REGISTRAR
HEALTH2WORKS LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 7
HEALTH2WORKS LIMITED
BALANCE SHEET
AS AT 31 AUGUST 2025
31 August 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
233,655
252,934
Tangible assets
5
1,691
2,768
235,346
255,702
Current assets
Debtors
6
10,041
9,966
Cash at bank and in hand
48,839
245,653
58,880
255,619
Creditors: amounts falling due within one year
7
(190,144)
(305,181)
Net current liabilities
(131,264)
(49,562)
Net assets
104,082
206,140
Capital and reserves
Called up share capital
8
493
510
Share premium account
499,164
521,650
Profit and loss reserves
(395,575)
(316,020)
Total equity
104,082
206,140

For the financial year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 5 August 2026 and are signed on its behalf by:
Mr R D Marlow
Director
Company registration number 06983940 (England and Wales)
HEALTH2WORKS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 AUGUST 2025
- 2 -
Share capital
Share premium account
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 September 2023
902
521,650
(267,389)
255,163
Year ended 31 August 2024:
Loss and total comprehensive income for the year
-
-
(48,631)
(48,631)
Reduction of shares
8
(392)
-
0
-
0
(392)
Balance at 31 August 2024
510
521,650
(316,020)
206,140
Year ended 31 August 2025:
Loss and total comprehensive income for the year
-
-
(79,555)
(79,555)
Reduction of shares
8
(17)
(22,486)
-
(22,503)
Balance at 31 August 2025
493
499,164
(395,575)
104,082
HEALTH2WORKS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
- 3 -
1
Accounting policies
Company information

Health2works Limited is a private company limited by shares incorporated in England and Wales. The registered office is 17 Hugo Street, Leek, Staffordshire, ST13 5PE.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recover able.

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
10 years straight line
Intellectual property
5 years straight line
HEALTH2WORKS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 4 -
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
5 years straight line
Computers
3 years straight line
1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.7
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash at bank only.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include other debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including tax ation and social security, trade credit o rs and other creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

HEALTH2WORKS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 5 -
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
3
3
4
Intangible fixed assets
Development costs
Intellectual property
Total
£
£
£
Cost
At 1 September 2024
1,169,406
505,000
1,674,406
Additions
50,666
-
0
50,666
At 31 August 2025
1,220,072
505,000
1,725,072
Amortisation and impairment
At 1 September 2024
916,472
505,000
1,421,472
Amortisation charged for the year
69,945
-
0
69,945
At 31 August 2025
986,417
505,000
1,491,417
Carrying amount
At 31 August 2025
233,655
-
0
233,655
At 31 August 2024
252,934
-
0
252,934
HEALTH2WORKS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 6 -
5
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 September 2024 and 31 August 2025
3,323
Depreciation and impairment
At 1 September 2024
555
Depreciation charged in the year
1,077
At 31 August 2025
1,632
Carrying amount
At 31 August 2025
1,691
At 31 August 2024
2,768
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
10,041
9,966
7
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
30,400
-
0
Taxation and social security
4,797
10,807
Other creditors
154,947
294,374
190,144
305,181
8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 1p each
49,283
50,954
493
510

During the year, the company entered into an agreement to acquire 1,671 Ordinary £0.01 shares of its own capital for an aggregate consideration of £22,503. The consideration was funded out of capital in accordance with section 692(1ZA) of the Companies Act 2006.

HEALTH2WORKS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 7 -
9
Directors' transactions

Loans to directors are interest free and repayable on demand.

Loans
% Rate
Opening balance
Closing balance
£
£
Loan
-
9,631
9,631
9,631
9,631
10
Events after the reporting date

Included within other debtors is a balance of £9,631 due from a director. On 8th March 2026 this director died and the board agreed to write off this loan balance.

11
Related party transactions

Included within other creditors are balances totalling £1,780 (202 4: £1,78 0) due to company directors. This balance is interest free and repayable on demand.

2025-08-31 2024-09-01 false false false 05 August 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr R D Marlow Mr S A Pashley Mr S A Robbins Mr P Fletcher 06983940 2024-09-01 2025-08-31 06983940 2025-08-31 06983940 2024-08-31 06983940 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-08-31 06983940 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2025-08-31 06983940 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-08-31 06983940 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-08-31 06983940 core:OtherPropertyPlantEquipment 2025-08-31 06983940 core:OtherPropertyPlantEquipment 2024-08-31 06983940 core:CurrentFinancialInstruments core:WithinOneYear 2025-08-31 06983940 core:CurrentFinancialInstruments core:WithinOneYear 2024-08-31 06983940 core:CurrentFinancialInstruments 2025-08-31 06983940 core:CurrentFinancialInstruments 2024-08-31 06983940 core:ShareCapital 2025-08-31 06983940 core:ShareCapital 2024-08-31 06983940 core:SharePremium 2025-08-31 06983940 core:SharePremium 2024-08-31 06983940 core:RetainedEarningsAccumulatedLosses 2025-08-31 06983940 core:RetainedEarningsAccumulatedLosses 2024-08-31 06983940 core:ShareCapital 2023-08-31 06983940 core:SharePremium 2023-08-31 06983940 core:RetainedEarningsAccumulatedLosses 2023-08-31 06983940 core:ShareCapitalOrdinaryShareClass1 2025-08-31 06983940 core:ShareCapitalOrdinaryShareClass1 2024-08-31 06983940 bus:Director1 2024-09-01 2025-08-31 06983940 core:RetainedEarningsAccumulatedLosses 2023-09-01 2024-08-31 06983940 2023-09-01 2024-08-31 06983940 core:RetainedEarningsAccumulatedLosses 2024-09-01 2025-08-31 06983940 core:ShareCapital 2023-09-01 2024-08-31 06983940 core:SharePremium 2023-09-01 2024-08-31 06983940 core:IntangibleAssetsOtherThanGoodwill 2024-09-01 2025-08-31 06983940 core:FurnitureFittings 2024-09-01 2025-08-31 06983940 core:ComputerEquipment 2024-09-01 2025-08-31 06983940 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-08-31 06983940 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-08-31 06983940 2024-08-31 06983940 core:DevelopmentCostsCapitalisedDevelopmentExpenditure core:ExternallyAcquiredIntangibleAssets 2024-09-01 2025-08-31 06983940 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill core:ExternallyAcquiredIntangibleAssets 2024-09-01 2025-08-31 06983940 core:ExternallyAcquiredIntangibleAssets 2024-09-01 2025-08-31 06983940 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-09-01 2025-08-31 06983940 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-09-01 2025-08-31 06983940 core:OtherPropertyPlantEquipment 2024-08-31 06983940 core:OtherPropertyPlantEquipment 2024-09-01 2025-08-31 06983940 bus:OrdinaryShareClass1 2024-09-01 2025-08-31 06983940 bus:OrdinaryShareClass1 2025-08-31 06983940 bus:OrdinaryShareClass1 2024-08-31 06983940 bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 06983940 bus:FRS102 2024-09-01 2025-08-31 06983940 bus:AuditExemptWithAccountantsReport 2024-09-01 2025-08-31 06983940 bus:Director2 2024-09-01 2025-08-31 06983940 bus:Director3 2024-09-01 2025-08-31 06983940 bus:Director4 2024-09-01 2025-08-31 06983940 bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 06983940 bus:FullAccounts 2024-09-01 2025-08-31 xbrli:pure xbrli:shares iso4217:GBP